Page 35 - Christiana Care Focus October 2018
P. 35
| Pharmacy Services
*includes moxifloxacin (non-formulary)
Source: UHC; DOT = days of therapy;
FQ = fluoroquinolone. When comparing monthly trends each year, there has been a significant decrease in fluoroquinolone and aztreonam use, likely attributed to more thorough beta-lactam (penicillin) allergy assessments. Fluoroquinolones have been associated with increasing resistance, toxigenic C. difficile infections, as well as toxicity. Aztreonam has a lim- ited spectrum of activity, with increasing bacterial resistance and significant cost. These agents should be reserved for those with severe beta lactam allergies (anaphylaxis, hives, swelling, shortness of breath, edema).
FOCUS • OCTOBER 2018 33
